Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2010 1
2011 1
2012 1
2014 2
2016 3
2017 1
2018 1
2019 3
2020 2
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
The following terms were ignored: %, %, %
The following terms were not found in PubMed: 20VJ, 5BAuthor
Page 1
Operative versus non-operative treatment for closed, displaced, intra-articular fractures of the calcaneus: randomised controlled trial.
Griffin D, Parsons N, Shaw E, Kulikov Y, Hutchinson C, Thorogood M, Lamb SE; UK Heel Fracture Trial Investigators. Griffin D, et al. BMJ. 2014 Jul 24;349:g4483. doi: 10.1136/bmj.g4483. BMJ. 2014. PMID: 25059747 Free PMC article. Clinical Trial.
MAIN OUTCOME MEASURES: The primary outcome measure was patient reported Kerr-Atkins score for pain and function (scale 0-100, 100 being the best possible score) at two years after injury. Secondary outcomes were complications; hindfoot pain and function (American Orthopaed …
MAIN OUTCOME MEASURES: The primary outcome measure was patient reported Kerr-Atkins score for pain and function (scale 0-100, 100 bei …
Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial.
Gray R, Patel S, Ives N, Rick C, Woolley R, Muzerengi S, Gray A, Jenkinson C, McIntosh E, Wheatley K, Williams A, Clarke CE; PD MED Collaborative Group. Gray R, et al. JAMA Neurol. 2022 Feb 1;79(2):131-140. doi: 10.1001/jamaneurol.2021.4736. JAMA Neurol. 2022. PMID: 34962574 Free PMC article. Clinical Trial.
With regard to DRIs, participants in the MAO-B group had mean PDQ-39 mobility scores that were 4.2 points (95% CI, 0.4-7.9 points; P=.03) better than those of the COMT group and EuroQol 5-dimension 3-level (EQ-5D-3L) utility scores that were 0.05 points (95% CI, 0.003-0.09 …
With regard to DRIs, participants in the MAO-B group had mean PDQ-39 mobility scores that were 4.2 points (95% CI, 0.4-7.9 points; P=.03) be …
Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial.
PD Med Collaborative Group; Gray R, Ives N, Rick C, Patel S, Gray A, Jenkinson C, McIntosh E, Wheatley K, Williams A, Clarke CE. PD Med Collaborative Group, et al. Lancet. 2014 Sep 27;384(9949):1196-205. doi: 10.1016/S0140-6736(14)60683-8. Epub 2014 Jun 11. Lancet. 2014. PMID: 24928805 Clinical Trial.
PDQ-39 mobility scores were 1.4 points (95% CI 0.0-2.9, p=0.05) better in patients allocated MAOBI than in those allocated dopamine agonists. EQ-5D utility scores averaged 0.03 (95% CI 0.01-0.05; p=0.0002) better with levodopa than with levodopa-sparing therapy; rates of d …
PDQ-39 mobility scores were 1.4 points (95% CI 0.0-2.9, p=0.05) better in patients allocated MAOBI than in those allocated dopamine agonists …
Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma.
Bedke J, Rini BI, Plimack ER, Stus V, Gafanov R, Waddell T, Nosov D, Pouliot F, Soulières D, Melichar B, Vynnychenko I, Azevedo SJ, Borchiellini D, McDermott RS, Tamada S, Nguyen AM, Wan S, Perini RF, Rhoda Molife L, Atkins MB, Powles T. Bedke J, et al. Eur Urol. 2022 Oct;82(4):427-439. doi: 10.1016/j.eururo.2022.06.009. Epub 2022 Jul 15. Eur Urol. 2022. PMID: 35843776 Clinical Trial.
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: HRQoL end points were measured using the European Organisation for the Research and Treatment of Cancer Core (EORTC) Quality of Life Questionnaire (QLQ-C30), EQ-5D visual analog rating scale (VAS), and Functional Assessment of …
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: HRQoL end points were measured using the European Organisation for the Research and Treatment …
Estimates for quality of life loss due to Respiratory Syncytial Virus.
Hodgson D, Atkins KE, Baguelin M, Panovska-Griffiths J, Thorrington D, van Hoek AJ, Zhao H, Fragaszy E, Hayward AC, Pebody R. Hodgson D, et al. Influenza Other Respir Viruses. 2020 Jan;14(1):19-27. doi: 10.1111/irv.12686. Epub 2019 Oct 18. Influenza Other Respir Viruses. 2020. PMID: 31625688 Free PMC article.
All participants were asked to complete questions regarding their health during the infection, with the suspected cases additionally providing health-related quality of life (HR-QoL) loss estimates by completing EQ-5D-3L-Y or EQ-5D-3L instruments. We used the respon …
All participants were asked to complete questions regarding their health during the infection, with the suspected cases additionally providi …
Health-related quality of life in survivors of septic shock: 6-month follow-up from the ADRENAL trial.
Hammond NE, Finfer SR, Li Q, Taylor C, Cohen J, Arabi Y, Bellomo R, Billot L, Harward M, Joyce C, McArthur C, Myburgh J, Perner A, Rajbhandari D, Rhodes A, Thompson K, Webb S, Venkatesh B; ADRENAL Trial Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Hammond NE, et al. Intensive Care Med. 2020 Sep;46(9):1696-1706. doi: 10.1007/s00134-020-06169-1. Epub 2020 Jul 16. Intensive Care Med. 2020. PMID: 32676679
Of these 2151 patients (85.3%-1080 hydrocortisone and 1071 placebo) completed 6-month follow-up. Overall, at 6 months the mean EQ-5D-5L visual analogue scale (VAS) was 70.8, mean utility score 59.4. ...Bacteraemia was not associated with worse HRQoL in any domains of the E …
Of these 2151 patients (85.3%-1080 hydrocortisone and 1071 placebo) completed 6-month follow-up. Overall, at 6 months the mean EQ-5D- …
Patient confidence and quality of life in idiopathic pulmonary fibrosis and sarcoidosis.
Kotecha J, Atkins C, Wilson A. Kotecha J, et al. Sarcoidosis Vasc Diffuse Lung Dis. 2016 Dec 23;33(4):341-348. Sarcoidosis Vasc Diffuse Lung Dis. 2016. PMID: 28079846
METHODS: Study participants self-completed seven questionnaires: Hospital Anxiety and Depression Scale, EuroQol 5D (EQ5D), King's Brief Interstitial Lung Disease questionnaire, St George's Respiratory Questionnaire, MRC dyspnoea scale, Fatigue Assessment Scale and a non-va …
METHODS: Study participants self-completed seven questionnaires: Hospital Anxiety and Depression Scale, EuroQol 5D (EQ5D), King's Bri …
Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis.
McDermott DF, Shah R, Gupte-Singh K, Sabater J, Luo L, Botteman M, Rao S, Regan MM, Atkins M. McDermott DF, et al. Qual Life Res. 2019 Jan;28(1):109-119. doi: 10.1007/s11136-018-1984-3. Epub 2018 Sep 6. Qual Life Res. 2019. PMID: 30191365 Clinical Trial.
Sensitivity analyses included varying utilities of TOX and REL; Q-TWiST gains at different follow-up times were calculated using EQ-5D-3L utilities from the trial. Relative Q-TWiST gain of 10% was considered clinically important. ...
Sensitivity analyses included varying utilities of TOX and REL; Q-TWiST gains at different follow-up times were calculated using EQ-5D …
Cost-effectiveness of oral versus intravenous antibiotics (OVIVA) in patients with bone and joint infection: evidence from a non-inferiority trial.
McMeekin N, Geue C, Briggs A, Rombach I, Li HK, Bejon P, McNally M, Atkins BL, Ferguson J, Scarborough M; OVIVA collaborators. McMeekin N, et al. Wellcome Open Res. 2019 Jul 17;4:108. doi: 10.12688/wellcomeopenres.15314.4. eCollection 2019. Wellcome Open Res. 2019. PMID: 31930174 Free PMC article.
Methods: A cost-utility analysis was carried out, the main economic outcome measure was the quality adjusted life-year, measured using the EQ-5D-3L questionnaire, combined with costs to estimate cost-effectiveness over 12-months follow-up. ...
Methods: A cost-utility analysis was carried out, the main economic outcome measure was the quality adjusted life-year, measured using the E …
14 results